A new Yale-developed artificial intelligence (AI) platform can detect individuals at risk for amyloid cardiomyopathy, an underdiagnosed cardiac condition, using data from a quick and accessible heart test.
HCTI signs MOU which details planned North American Joint Venture.The Proposed venture would deploy humanoid robots to assist with patient toileting and hygiene care, easing the physical burden on nursing teams while preserving patient dignity
Developed to fit around nursing workflows, ClinicalKey Nursing AI gives nurses fast, traceable answers to clinical questions at the point of care.
A new AI-based model can predict where glioblastoma is most likely to return after initial surgery, potentially giving doctors a chance to treat it before it becomes visible on MRI.
Pancreatic cancer does not respond to most immunotherapies, but RAS inhibitors could alter tumors to make them more sensitive to a novel immunotherapeutic approach. In pancreatic tumors with RAS mutations, RAS inhibitors cause massive cell death and reduce immunosuppression. These changes tend to be temporary because tumors develop resistance to the therapy.
SEOUL, South Korea, Sept. 22, 2026 /PRNewswire/ — AIMD Inc., a Korean medical technology company specializing in AI-powered emergency care, announced the global expansion of A-LRYNGO™, the world’s first AI-guided video laryngoscope with real-time automatic glottis recognition, as the company advances AI-guided airway management into clinical practice worldwide.
Tracking down senescent cells, which accumulate as we age, could help diagnose age-related disorders and guide researchers working on new treatments.
DeepHealth has announced FDA 510(k) clearance for Chest XRay, one of the first FDA-cleared chest X-ray computer-aided detection (CADe) solutions built on a foundation model that detects and localizes suspected thoracic abnormalities on chest radiographs. The clearance marks a significant step in the company’s vision of bringing intelligence into every stage of the imaging experience.
A new study published in the journal npj Breast Cancer demonstrates that an artificial intelligence (AI) model offers more accurate predictions of recurrence risk in patients with early-stage breast cancer than the widely used 21-gene Recurrence Score. This research, conducted by a team from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Caris Life Sciences, specifically targets hormone receptor-positive (HR+) and HER2-negative disease, the most common subtype of breast cancer, which accounts for about half of all breast cancer cases in the United States.
This patient-specific method, called xvr, helps doctors use X-rays for surgical navigation in fields such as orthopedics and neurosurgery.